Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

CRXA said it will amend its BLA for Bexxar to treat low-grade or transformed low-grade non-Hodgkin's lymphoma. The decision follows a March complete review letter from the FDA for Bexxar in which the ...